Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
Q32 Bio Inc.
(Name of Issuer)
Common stock, par value $0.0001 per share
(Title of Class of Securities)
746964105
(CUSIP Number)
March 25, 2024
(Date of Event Which Requires Filing of this Statement)
Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:
|
☐
|
Rule 13d-1(b)
|
|
☐
|
Rule 13d-1(c)
|
| ☒ |
Rule 13d-1(d)
|
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures
provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
|
Bristol-Myers Squibb Company
|
|
|
|||
|
|
|
||||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
||||
|
(a)☐
|
|||||
|
(b)☐
|
|
|
|||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
Delaware
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
|
759,145
|
|
|
|||
|
|
|
||||
|
6
|
SHARED VOTING POWER
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
759,145
|
|
|
|||
|
|
|
||||
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
759,145
|
|
|
|||
|
|
|
||||
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
|
☐
|
|
|
|||
|
|
|
||||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
|
6.23%(1)
|
|
|
|||
|
|
|
||||
|
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
|
CO
|
|
|
|||
|
|
|
||||
(1) Calculated based upon 12,180,701 shares of common stock, par value $0.0001 per share, outstanding as of November 1, 2024, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024.
| Item 1(a). |
Name of Issuer
|
Q32 Bio Inc. (the “Issuer”)
| Item 1(b). |
Address of the Issuer’s Principal Executive Offices
|
830 Winter Street
Waltham, MA 02451
| Item 2(a). |
Names of Persons Filing
|
This statement is filed by the Bristol-Myers Squibb Company, referred to herein as the “Reporting Person.”
| Item 2(b). |
Address of the Principal Business Office, or if none, Residence
|
Route 206 & Province Line Road
Princeton, NJ 08543
| Item 2(c). |
Citizenship
|
See response to Item 4 on the cover page.
| Item 2(d). |
Title of Class of Securities
|
Common stock, par value $0.0001 per share
| Item 2(e). |
CUSIP Number
|
746964105
| Item 3. |
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
Not Applicable
| Item 4. |
Ownership
|
| (a) |
Amount beneficially owned:
|
See response to Item 9 on the cover page.
|
(b)
|
Percent of Class:
|
See response to Item 11 on the cover page.
|
(c)
|
Number of shares as to which the Reporting Person has:
|
| (i) |
Sole power to vote or to direct the vote:
|
See response to Item 5 on the cover page.
| (ii) |
Shared power to vote or to direct the vote:
|
See response to Item 6 on the cover page.
| (iii) |
Sole power to dispose or to direct the disposition of:
|
See response to Item 7 on the cover page.
| (iv) |
Shared power to dispose or to direct the disposition of:
|
See response to Item 8 on the cover page.
The filing of this Statement shall not be construed as an admission that the Reporting Person is, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this
Statement.
| Item 5. |
Ownership of Five Percent or Less of a Class
|
Not Applicable.
| Item 6. |
Ownership of More than Five Percent on Behalf of Another Person
|
Not Applicable.
| Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
|
Not Applicable.
| Item 8. |
Identification and Classification of Members of the Group
|
Not Applicable.
| Item 9. |
Notice of Dissolution of Group
|
Not Applicable
| Item 10. |
Certification
|
Not Applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Dated: November 13, 2024
|
|||
|
Bristol-Myers Squibb Company
|
|||
|
By:
|
/s/ Amy Fallone | ||
|
Name: Amy Fallone
|
|||
|
Title: Corporate Secretary
|
|||